Pharmacodynamic of cilostazol for anti-altitude hypoxia.
10.11817/j.issn.1672-7347.2022.200972
- Author:
Xue LI
1
;
Rong WANG
2
;
Yan HUO
2
;
Anpeng ZHAO
3
;
Wenbin LI
4
;
Shilan FENG
5
Author Information
1. School of Pharmacy, Lanzhou University, Lanzhou 730000. lixue18@lzu.edu.cn.
2. School of Pharmacy, Lanzhou University, Lanzhou 730000.
3. Pharmacy Department, the 940th Hospital of Joint Logistics Support Force, Lanzhou 730050, China.
4. Pharmacy Department, the 940th Hospital of Joint Logistics Support Force, Lanzhou 730050, China. yfcs2002@163.com.
5. School of Pharmacy, Lanzhou University, Lanzhou 730000. fengshl@ lzu.edu.cn.
- Publication Type:Journal Article
- Keywords:
anti-hypoxia;
cilostazol;
rapid to high altitude;
tissue damage
- MeSH:
Altitude Sickness;
Animals;
Cilostazol/therapeutic use*;
Hypoxia/drug therapy*;
Interleukin-6/pharmacology*;
Male;
Mice;
Mice, Inbred BALB C;
Oxidative Stress;
Oxygen;
Rats;
Rats, Wistar;
Superoxide Dismutase/metabolism*;
Tumor Necrosis Factor-alpha/pharmacology*
- From:
Journal of Central South University(Medical Sciences)
2022;47(2):202-210
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:The plateau environment is characterized by low oxygen partial pressure, leading to the reduction of oxygen carrying capacity in alveoli and the reduction of available oxygen in tissues, and thus causing tissue damage. Cilostazol is a phosphodiesterase III inhibitor that has been reported to increase the oxygen release of hemoglobin (Hb) in tissues. This study aims to explore the anti-hypoxic activity of cilostazol and its anti-hypoxic effect.
METHODS:A total of 40 male BALB/C mice were randomly divided into a low-dose cilostazol (6.5 mg/kg) group, a medium-dose (13 mg/kg) group, a high-dose (26 mg/kg) group, and a control group. The atmospheric airtight hypoxia experiment was used to investigate the anti-hypoxic activity of cilostazol and to screen the optimal dosage. Twenty-four male Wistar rats were randomly divided into a normoxia control group, a hypoxia model group, an acetazolamide (22.33 mg/kg) group, and a cilostazol (9 mg/kg) group. After 3 days of hypoxia in the 4 010 m high altitude, blood from the abdominal aorta was collected to determine blood gas indicators, the levels of IL-6 and TNF-α in plasma were determined by enzyme-linked immunosorbent assay, and the levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutataione (GSH) were measured. The degree of pathological damage for rat tissues was observed with HE staining.
RESULTS:Compared with the control group, the survival time of mice in the low, medium, and high dose group of cilostazol was significantly prolonged, and the survival time of mice in the medium dose group was the longest, with an extension rate at 29.34%, so the medium dose was the best dose. Compared with the hypoxia model group, the P50 (oxygen partial pressure at Hb oxygen saturation of 50%) value of rats in the cilostazol group was significantly increased by 1.03%; Hb and Hct were significantly reduced by 8.46% and 8.43%, and the levels of IL-6 and TNF-α in plasma were reduced by 50.65% and 30.77%. The MDA contents in heart, brain, lung, liver, and kidney tissues were reduced by 37.12%, 29.55%, 25.00%, 39.34%, and 21.47%, respectively. The SOD activities were increased by 94.93%, 9.14%, 9.42%, 13.29%, and 20.80%, respectively. The GSH contents were increased by 95.24%, 28.62%, 28.57%, 20.80%, and 44.00%, respectively. The results of HE staining showed that compared with the hypoxia model group, cilostazol significantly improved the damage of heart, lung, and kidney tissues in rats after hypoxia.
CONCLUSIONS:Cilostazol can significantly improve the oxidative stress and inflammatory reaction caused by rapid altitude hypoxia, and it has a significant protective effect on tissue damage caused by hypoxia, suggesting that it has obvious anti-hypoxic activity.
